CheckMate 153 study: are age and performance status relevant for immune checkpoint inhibitor efficacy?
Sign Up to like & getrecommendations! Published in 2019 at "Translational lung cancer research"
DOI: 10.21037/tlcr.2019.12.26
Abstract: Immune checkpoint inhibitors (ICIs), including pembrolizumab and nivolumab, both monoclonal antibodies against programmed cell death-1 (PD-1), and antibodies targeting the programmed cell death receptor ligand-1 (PD-L1) such as atezolizumab or durvalumab, have heralded impressive therapeutic… read more here.
Keywords: immune checkpoint; age performance; study age; 153 study ... See more keywords